FDA
approval
· 2021-03-05
FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)
Summary
Ardelyx submitted a supplemental application to the FDA for IBSRELA (tenapanor hydrochloride) related to its labeling for irritable bowel syndrome with constipa…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for IBSRELA (TENAPANOR HYDROCHLORIDE)